Laura Piddock 💙

Advancing global antibiotic research, development and access | Nature Medicine nature.com/articles/s4159…

Exploring the history and uncertain future of antibiotics bbc.co.uk/sounds/series/…

GARDP’s AntibioticDB, an open-access database cataloguing 3,000+ antibacterial agents, has just been updated with a new feature: compound pages now display 2D chemical structures and molecular weights. A valuable tool for researchers working to address #AMR. 🔗 Explore the update: antibioticdb.com/AdbCompoundsFo…

🚀 Exciting news! Registration is now open for #ACC2026- a *FREE* virtual conference co-organized by GARDP & @BSACandJAC, joined this year by @ADVANCE__ID & @MahidolU. 🌍 Join us as we dive into the latest advances in antimicrobial discovery, development and access. 📅 4 & 5 February 2026 Don’t miss out! 🔗 bsac.eventsair.com/antimicrobial-…

@LauraPiddock @mbiojournal @josebengoechea @TarasenkoAnita @EijkelkampLab @JeremyJBarr Looking for TolC phages in high throughput was one of the major motivations for our Phage DisCo technique! journals.asm.org/doi/10.1128/ms…

@mbiojournal @josebengoechea @TarasenkoAnita @EijkelkampLab @JeremyJBarr I was an early advocate of this with TolC as a target for a phage - see the article here journals.asm.org/doi/10.1128/ae…

Can phages turn bacterial resistance into vulnerability? This new #mBio minireview explores how phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens. #PhageTherapy #AMR #antibiotic @TarasenkoAnita @EijkelkampLab @JeremyJBarr doi.org/10.1128/mBio.0…

-154 million mothers didn’t have to cry over a child’s grave. - 10.2 BILLION years of life added. - Unquantifiable suffering of children (pain, paralysis, seizures, pneumonia, etc) averted. Vaccines are an absolute good.

what a wonderful antidote to the horrors of the world

Meet REVIVE, your global antimicrobial R&D community and platform🌍 Created by GARDP, REVIVE connects and supports researchers, clinicians and innovators working to address #AMR. It is where you can follow what is happening in antimicrobial R&D, learn from past breakthroughs and get practical insights for the challenges ahead. With fresh, high-quality content you can trust, REVIVE answers the questions that matter most in antimicrobial R&D. Here you will find: 💡 Expert-led webinars on antimicrobial R&D and stewardship in low- and middle-income countries 📚 Curated learning resources such as Viewpoint articles by leading AMR experts, an online conference and Encyclopaedia 🤝 A global network experts across regions and disciplines. 🔗 Explore REVIVE: revive.gardp.org

#Bacteriophages could offer hope where antibiotics are failing, especially in #LMICs At a workshop hosted by the @GlobalAMRHub, GARDP and global experts discussed how to design trials that can scale, shape regulation through dialogue and ensure equity by involving the most affected countries from the very start. The full report is now live 👇globalamrhub.org/publications/w…

Syphilis is resurging with congenital cases rising too. At our upcoming REVIVE webinar, infectious disease experts will share what’s working, what’s not and why new treatments are urgently needed. 📅 19 August 2025, 17:00-18:30 CEST 📍 Online Register here: attendee.gotowebinar.com/register/44694…

Out Now! Rethinking approaches to overcome infectious disease bit.ly/476sEZu #InfectiousDiseases #Microbiology #HealthCare

📊 Inside AntibioticDB AntibioticDB holds data on 3,000+ antibacterial compounds—from traditional antibiotics to experimental therapies like phages and antivirulence agents🧬🦠📈🧪🔍 With new tools like wildcard search, chemical identifiers, and smarter filters, AntibioticDB is a launching pad for the next generation of antibiotic R&D. 🔗 Start exploring revive.gardp.org/antibioticdb/ @GuidetoPHARM #AMR #OpenAccess #REVIVE

Call for individual research grants 2026📣 ESCMID offers research grants to conduct clinical studies, experimental animal studies, or a combination of approaches. For this year's call, the focus is on bacterial infections ⏰Apply by 10 Sept 💡Learn more: ow.ly/Zral50WaC7K

👏FDA accepts New Drug Application for zoliflodacin — an investigational first-in-class oral antibiotic for uncomplicated #gonorrhoea. 🌍 Developed in collaboration with @InnovivaSTx, it could become the first new oral antibiotic for gonorrhoea in over 30 years. 🔗 Read the full press release here: bit.ly/44949ZF #AMR #STIs #PublicHealth #Zoliflodacin #ThisIsBig #GARDP

@gardp_amr @innovivastx Yaay! 👏🏻👏🏻🎊🎉

🎓 Are you an early-career researcher in clinical microbiology or infectious diseases? GARDP is offering 5 grants to attend a top postgraduate course by @ecraid and @ESCMID. 📅 28–30 October 2025 📍 Athens, Greece 🌍 Priority for applicants from low- and middle-income countries ✈️ Travel costs not covered Apply now 👉 ecraid.eu/news/postgradu… #AMR #ClinicalResearch #Grants

Check out this new scheme for Class D b-lactamases. SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering | Antimicrobial Agents and Chemotherapy journals.asm.org/doi/10.1128/aa…

🎥 The #ACC2025 recording is now available! From resistance trends to PK/PD and clinical challenges, watch the full conference to catch key insights for researchers, clinicians, and AMR specialists. ▶️ Start watching: revive.gardp.org/antimicrobial-…

🚨 This is Big! New GARDP research shows that people with multidrug-resistant infections in LMICs are not receiving the appropriate antibiotics because of large gaps in access. Improving access and developing new antibiotics must be a priority, 📖 Read the study 👇 thelancet.com/journals/lanin…

New online! The global resistance problem and the clinical antibacterial pipeline nature.com/articles/s4157…